Geispitzen, France

Marie-Pierre Filliot

USPTO Granted Patents = 1 

Average Co-Inventor Count = 6.0

ph-index = 1


Company Filing History:


Years Active: 2015

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovations of Marie-Pierre Filliot: A Focus on Pharmaceutical Advancements

Introduction

Marie-Pierre Filliot is an inventive force in the pharmaceutical industry, based in Geispitzen, France. With a dedication to developing innovative treatments, she holds a significant patent that showcases her contribution to modern medicine.

Latest Patents

Filliot's patent, titled "Pharmaceutical compositions, dosage forms and new forms of the compound of formula (I), and methods of use thereof," presents a groundbreaking discovery. This invention introduces a novel crystalline anhydrous form of a complex compound designed for the treatment or prevention of conditions that require platelet ADP receptor inhibition, particularly focusing on P2Y inhibition in humans. The patent outlines not only the unique chemical formulation but also the methods involved in creating this crystalline form and its application in solid oral formulations.

Career Highlights

Filliot has made significant strides in her career, most notably as a part of Portola Pharmaceuticals, Inc. Here, she focuses on the development of innovative pharmaceutical solutions that address pressing medical concerns. Her work reflects a strong commitment to enhancing patient care through advanced therapeutic options.

Collaborations

Throughout her career, Filliot has collaborated with dedicated professionals in her field. One notable coworker is Nicole Bieri, who shares her passion for pharmaceutical innovation. Together, they contribute to the advancement of medical treatments, highlighting the importance of teamwork in scientific research and development.

Conclusion

Marie-Pierre Filliot exemplifies the spirit of innovation in the pharmaceutical industry. Her patent reflects a significant leap in medical treatment options, combining her expertise with collaborative endeavors. As she continues her work at Portola Pharmaceuticals, her contributions will undoubtedly influence future developments in healthcare.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…